Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
|Therapy Name||Anti-PSCA(dCH2)BBz-CAR T-cells|
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|Anti-PSCA(dCH2)BBz-CAR T-cells||anti-PSCA-CAR-4-1BB/TCRzeta-CD19t-expressing T lymphocytes||Anti-PSCA(dCH2)BBz-CAR T-cells are T-cells that have been engineered to express a PSCA-targeted chimeric antigen receptor (CAR) containing a 4-1BB signaling domain and truncated CD19, which may increase death of PSCA-expressing tumor cells and and decrease tumor growth (PMID: 29308300).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status|
|NCT03873805||Phase I||Cyclophosphamide + Fludarabine Anti-PSCA(dCH2)BBz-CAR T-cells||PSCA-CAR T Cells in Treating Patients With PSCA+ Metastatic Castration Resistant Prostate Cancer||Recruiting|